The high heritability of schizophrenia has stimulated much work aimed at identifying susceptibility genes using positional genetics. However, difficulties in obtaining clear replicated linkages have led to the scepticism that such approaches would ever be successful. Fortunately, there are now signs of real progress. Several strong and well-established linkages have emerged. Three of the best-supported regions are 6p24-22, 1q21-22 and 13q32-34. In these cases, single studies achieved genome-wide significance at Po0.05 and suggestive positive findings have also been reported in other samples. The other promising regions include 8p21-22, 6q21-25, 22q11-12, 5q21-q33, 10p15-p11 and 1q42. The study of chromosomal abnormalities in schizophrenia has also added to the evidence for susceptibility loci at 22q11 and 1q42. Recently, evidence implicating individual genes within some of the linked regions has been reported and more importantly replicated. The weight of evidence now favours NRG1 and DTNBP1 as susceptibility loci, though work remains before we understand precisely how genetic variation at each locus confers susceptibility and protection. The evidence for catechol-O-methyl transferase, RGS4 and G72 is promising but not yet persuasive. While further replications remain the top priority, the respective contributions of each gene, relationships with aspects of the phenotype, the possibility of epistatic interactions between genes and functional interactions between the gene products will all need investigation. The ability of positional genetics to implicate novel genes and pathways will open up new vistas for neurobiological research, and all the signs are that it is now poised to deliver crucial insights into the nature of schizophrenia.
Introduction
Understanding the aetiology and pathogenesis of schizophrenia is one of the most important challenges facing psychiatry. Some progress has been made, and the currently prevailing view is that schizophrenia is a neurodevelopmental disorder leading to abnormalities of synaptic connectivity. 1 However, one of the few things we know for certain is that individual differences in liability are very largely genetic, with heritability estimates of around 80%. 2 It is therefore not surprising that, since molecular genetic approaches became widely available in the late 1980s, many groups have been seeking to identify the allelic variants conferring susceptibility. Early studies sought to identify families with many affected relatives that are segregating rare alleles of large effect, a strategy that was effective in other common disorders such as Alzheimer's disease. [3] [4] [5] Unfortunately, this approach proved unsuccessful for schizophrenia and until recently it was possible to argue that the only achievement of molecular genetic studies of schizophrenia had been to demonstrate that such families are rare or nonexistent. Difficulties in obtaining clear replicated linkages in schizophrenia and other common disorders led to increasing scepticism that such approaches would ever be successful. However, for the first time in 15 years of intensive international effort, we can discern signs of real progress. Several strong and well-established linkages have emerged, and evidence implicating individual genes within some of the linked regions has been reported and more importantly replicated. These successes reflect not only advances in genomics and the availability of the draft human genome sequence, but also a greater realisation of the likely complexity of the underlying genetic architecture of schizophrenia and its implications for study design and the interpretation of data.
Mode of transmission
It is clear from studies on different classes of relatives that the recurrence risk decreases too rapidly with increasing genetic distance from the proband for schizophrenia to be a single-gene disorder or collec-tion of single-gene disorders even when incomplete penetrance is taken into account. Rather, the mode of transmission like that of other common disorders is complex and non-Mendelian. 6, 7 The commonest mode of transmission is probably oligogenic, polygenic or a mixture of the two with a threshold effect. 8 However, the number of susceptibility loci, the disease risk conferred by each locus, the extent of genetic heterogeneity and the degree of interaction among loci, all remain unknown. Risch 9 has calculated that the data for recurrence risks in the relatives of probands with schizophrenia are incompatible with the existence of a single locus conferring a relative risk in siblings (l s ) of more than 3 and, unless extreme epistasis exists, models with two or three loci of l s r2 are more plausible. It should be emphasised that these calculations are based upon the assumption of homogeneity and refer to population-wide l s . It is quite possible that alleles of larger effect are operating in some groups of patients, for example, families chosen for having a high density of illness. However, it has also been demonstrated that such families would be expected to occur even under polygenic inheritance and their existence does not force the conclusion that alleles of large effect exist. 7 The predicted lack of simple one-to-one relationships between genotype and phenotype makes the task of identifying susceptibility genes difficult. In particular, it clearly implies the need for large sample sizes both for initial findings and even more so for replication. 10 
Defining the phenotype
The ignorance of pathogenesis and the lack of biological markers mean that the disorder is effectively syndromic with diagnosis based upon a combination of heterophenomenology and clinical observation. In view of the quite extensive clinical heterogeneity, many attempts have been made to delineate etiologically distinct subgroups. However, these have been largely unsuccessful. 11 In spite of this, the use of structured and semistructured interviews, together with explicit operational diagnostic criteria, allows high degrees of diagnostic reliability to be achieved. Moreover, as we have seen, the syndrome so defined has a high heritability and it should, in principle, be possible to subject it to molecular genetic analysis. However, we also have to accept that schizophrenia, as defined by current diagnostic criteria, may well include a number of heterogeneous disease processes and that identifying genes and other aetiological factors would be easier if it were possible to distinguish reliably between them.
Family, twin and adoption studies have shown that the phenotype extends beyond the core diagnosis of schizophrenia to include a spectrum of disorders including mainly schizophrenic schizoaffective disorder, and schizotypal personality disorder. 12, 13 However, the limits of this spectrum and its relationship to other psychoses, affective and nonaffective, and nonpsychotic affective disorders remain uncertain. [14] [15] [16] Finally, although it is clear that individual differences in liability to schizophrenia are substantially genetic, we have no clear idea what form this 'liability' actually takes. That is to say, we are not yet able to identify the endophenotypes that are intermediate between genetic predisposition and the clinical phenotype of schizophrenia. 17, 18 However, in spite of these problems and uncertainties and the difficulties that ensue, schizophrenia is a compelling candidate for studies aimed at identifying disease genes. This is true not only because of its high heritability, but also because, notwithstanding improvements in neuroimaging and gene-expression studies in autopsy material, the brain is still difficult to study directly, and interpretation of cause and effect is problematic.
Approaches to finding genes
There are three main approaches to identifying disease genes in human populations: linkage and association studies using genetic polymorphisms and the identification of chromosomal abnormalities in patients.
In linkage studies, the objective is to identify regions of the genome that are cotransmitted with the disease in families containing two or more affected individuals. Since it is possible to screen the whole genome for the presence of such regions using a few hundred evenly spaced genetic markers, linkage has the potential to locate disease genes by chromosomal position alone, without any prior knowledge of disease aetiology. Unfortunately, whereas it is ideally suited to detecting genes of large effect in genetically simple disorders, its power to detect genes of moderate to small effect is limited, and large numbers of families are required to locate genes for complex disorders such as schizophrenia. 10 These limitations of linkage studies have led to an increasing interest in the association design which is, under most circumstances, more powerful for detecting genes of small effect than linkage. 19 In association studies, the aim is to detect alleles that are more (or less) common in cases than in the general population. However, in contrast to linkage where a few hundred markers suffice, even optimists concede that, at the very least, several hundreds of thousands of markers will be required to screen the whole genome by association in outbred populations. 20 Researchers have therefore been required to select specific candidate genes for investigation by association. Selection may be on the grounds that a gene is a functional candidate (that is, the gene encodes a protein implicated by an aetiological hypothesis), a positional candidate (that is, it maps to a region implicated by previous linkage studies) or a combination of the two. Owing to doubts concerning the robustness of linkage findings in schizophrenia, most studies to date have focused upon functional candidate genes.
There are a number of potential problems with association studies that have been reviewed elsewhere. 21, 22 It is, however, worth reminding ourselves that most studies to date have not had sufficient power to detect or confirm the presence of alleles of small effect. For example, if we assume a disease allele with a population frequency of 0.2, which confers risk of disease at an odds ratio of 1.4, sample sizes of 500 cases and 500 controls are required for a power of 0.9 to detect association at P¼0.05. The combination of low power and low prior probability implies that when positive associations are reported, even in the best-designed studies, it remains far more likely that the finding is due to chance than to a true association.
Advances in genomics are increasingly allowing more systematic approaches to association. While whole-genome association studies based on hundreds of thousands of markers remain beyond the limit of feasibility for most academic laboratories, it is now at least feasible to search a linked region systematically for association, either in an academic lab, or as people are increasingly doing, by purchasing the services of a genome analysis 'factory'. Second, now that the location of most genes is known, it is also possible to systematically target the related functional systems, which, when viewed as a unit, together have a greater prior probability than does a single candidate gene. Third, high-throughput microarray platforms are capable of simultaneously generating and analysing the expression of many thousands of genes. 23, 24 This gives us the potential to identify candidate genes on the basis of dysregulation in tissues from subjects with any given disease. While such methods have huge potential, their limitations are particularly apparent when they are applied to the analysis of human brain. These include variation in expression as a result of polymorphism in genes unrelated to disease, variation in the environment, variation as a consequence of the phenotype (eg self-neglect, drugs, nutrition), variation in mRNA quality (as a result, for example, of postmortem delay or antemortem agonal state), variation in cause of death and variation in tissue preparation. Nevertheless, highly parallel expression studies do offer a complementary approach to linkage, in that they are genome-wide, have the potential to reveal novel molecular mechanisms that contribute to disease, and can provide us an alternative source of candidate genes derived without regard to our preconceptions of disease mechanisms.
It is also possible to identify chromosomal regions potentially harbouring susceptibility genes by identifying chromosomal abnormalities in affected individuals. Cytogenetic anomalies, such as translocations and deletions, may be pathogenic through several mechanisms: direct disruption of a gene or genes, the formation of a new gene comprised of a fusion of two genes that are normally spatially separated, indirect disruption of the function of neighbouring genes by the so-called position effect or an alteration of gene dosage in the case of deletions, duplications and unbalanced translocations. It is also possible for a cytogenetic abnormality to be cotransmitted with disease in a particular family, by virtue of genetic linkage between the abnormality and the true disease locus. Owing to the high prevalence of schizophrenia, a single incidence of a cytogenetic abnormality is insufficient to suggest causality. In order to warrant further investigation, it should be shown to exist in greater frequencies in affected individuals, to disrupt a region already implicated by genetic analyses, or to show cosegregation with the condition in affected families.
Linkage studies
The results of linkage studies of schizophrenia have seemed to some to be disappointing with positive studies often falling short of being compelling and failures to replicate being abundant. However, as more than 20 genome-wide studies have been reported and as sample sizes and hence power have increased, so replicated, positive linkages to several chromosomal regions have accumulated ( Figure 1) .
Three of the best-supported regions are 6p24-22, 1q21-22 and 13q32-34. In these cases, single studies achieved genome-wide significance at Po0.05, [25] [26] [27] that is, a linkage value that is expected less than once by chance in 20 complete genome scans. Moreover, in each case, suggestive positive findings have also been reported in other samples. [27] [28] [29] [30] [31] [32] [33] In two further regions, several groups have reported highly suggestive evidence for linkage. These are 8p21-22 26, 27, 29, [33] [34] [35] and 6q21-25. 31, [36] [37] [38] [39] The findings on 6q by Lindholm et al, 40 in an extended kindred from north Sweden, and those of Lerer et al, 39 in Arab-Israeli families, were highly significant. However, the linkage peaks in these studies are some 40 cM apart at 180 and 140 cM, respectively. Moreover, the positive findings in the other studies are even further centromeric at 100-120 cM. Location estimates in linkage studies of complex disorders are susceptible to a high degree of chance variation, 41 but it is also possible that the linkage data from 6q reflect the presence of more than one susceptibility gene. Other promising regions in which positive findings have been obtained from more than one study include 22q11-12, [42] [43] [44] [45] 5q21-q33, 32 None of the above regions has consistently been replicated in the majority of genome scans, and it is likely that some represent false positives. However, we should also expect true linkages to fail to replicate because loci with small population-wide effects require larger samples than those in which the original findings were obtained, 54, 55 and power for replication is often even less than assumed since initial studies tend to overestimate the effect sizes. 56 This may be a major problem as schizophrenia genome scan sample sizes have been small, with typical samples of between 20 and 100 families, while the largest published to date included 294 small pedigrees. 45 In fact, in human populations, replication studies are strictly speaking impossible as samples almost certainly differ in genetic architecture because of ethnicity, ascertainment, variation in exposure to environmental risks, and where there are multiple disease alleles, sampling variance. 57, 58 One solution, albeit flawed, 59 to the problems of power and replication is meta-analysis. A recent meta-analysis included 20 schizophrenia genome scans. 60 The number of loci meeting the aggregate criteria for significance was much greater than the number of loci expected by chance (Po0.001), revealing greater consistency than has been previously recognised. The authors concluded that schizophrenia loci are highly likely to be present in some, perhaps even all, of 2p-q, 5q, 3p, 11q, 6p, 1p-q, 22q11-12, 8p 20p, and 14pter-q13. Other regions were also implicated, but the evidence was somewhat weaker. These were 16p-q, 18q, 10p, 15q, 6q and 17q. Another meta-analysis 61 found significant results only on chromosomes 8p, 13q and 22q. The two studies differed in many important respects, including the fundamental approach, but it seems reasonable that because it was based upon a larger and more complete dataset, the study by Lewis and colleagues identified additional significant regions.
At the present time therefore, the linkage literature supports the predictions made by Risch 9 : it is highly unlikely that a commonly occurring locus of effect size l s 43 exists. Indeed, under the assumption of no dominance variance, Williams et al 62 were able to exclude susceptibility genes with an effect of l s ¼3 and 2 from 82.8 and 48.7% of the genome, respectively, while genes with an effect size of l s ¼1.5 could only be excluded from 9.3% of the genome. However, there is suggestive evidence implicating a number of regions, which is consistent with the existence of some susceptibility alleles of moderate effect (l s ¼1.5-3), and possibly uncommon loci of larger effect that can be identified in specific samples of large multiply affected families.
While uncertainties remain, it seems likely that several of the above loci are true positives. Three of the best-supported regions are 6p24-22, 1q21-22 and 13q32, with genome-wide significant evidence from at least one study and support from several others. A number of other regions have received support from multiple genome scans and, not surprisingly, are also supported by meta-analysis. It is difficult to indicate precisely for which regions the statistical evidence for linkage is sufficiently strong to warrant large-scale and expensive efforts aimed at cloning putative linked loci. Of course, the proof that a positive linkage is correct comes when the disease gene, or genes, is identified, and a number of linked regions are currently being subjected to detailed analysis with, in some instances, encouraging results. Another way of resolving uncertainty will be to study much larger samples, of say 600-800 nuclear families, which should be sufficient to detect susceptibility genes of moderate effect size, and may also allow detection of interactions between loci, relationships between allele sharing at particular loci and aspects of the phenotype and loci of smaller effect; collaborative studies of this sort should now become a priority. 10 
Cytogenetic abnormalities associated with schizophrenia
There have been numerous reports of associations between schizophrenia and chromosomal abnormalities, [63] [64] [65] but with two exceptions none has as yet provided convincing evidence to support the location of a gene conferring risk to schizophrenia. The first finding of interest is a (1;11)(q42;q14.3) balanced reciprocal translocation found to cosegregate with schizophrenia and other psychiatric disorders in a large Scottish family. 53, 66 This translocation generates a LOD score of 3.6 when the disease phenotype is restricted to schizophrenia, of 4.5 when the disease phenotype is restricted to affective disorders and of 7.1 when relatives with recurrent major depression, bipolar disorder or schizophrenia are all classed as affected. 53 Recently, the translocation has been reported to directly disrupt two genes on chromosome 1. These have been called DISC 1 and 2.
67 DISC 2 contains no ORF and may regulate DISC 1 expression via antisense RNA. 67 There is evidence that the DISC 1 protein may regulate cytoskeletal function and that truncation, as occurs in the translocation family, might contribute to schizophrenia by affecting neuronal functions dependent upon intact ctyoskeletal regulation such as neuronal migration, neurite architecture and intracellular transport. [68] [69] [70] Interestingly, DISC 1 and 2 are located close to the chromosome 1 markers implicated in the two Finnish linkage studies mentioned previously. 51, 52 However, until mutations have been identified in other samples 71 or convincing biological evidence implicating this locus has been obtained, the mechanism by which the translocation confers risk to mental illness remains obscure, and we cannot be sure whether genes or mechanisms of wider relevance have been identified.
The second finding of interest is the association between Velo-Cardio-Facial syndrome (VCFS) and schizophrenia. The VCFS, also known as DiGeorge or Shprintzen syndrome, is associated with small interstitial deletions of chromosome 22q11. The phenotype of VCFS is variable, but in addition to the characteristic core features of dysmorphology, abnormalities of the palate and congenital heart disease, there is strong evidence that individuals with VCFS have a dramatic increase in the risk of psychosis especially schizophrenia. 42, [72] [73] [74] Clearly, with an estimated prevalence of one in 4000 live births, one can estimate that VCFS cannot be responsible for more than a small fraction (B1%) of cases of schizophrenia, and this estimate is in keeping with empirical data. 75, 76 From the practical perspective, clinicians should be vigilant for VCFS, especially when psychosis occurs in the presence of other features, suggestive of the syndrome such as dysmorphology, mild learning disability or a history of cleft palate or congenital heart disease. 74, 77 However, from the perspective of the genetic researcher, the most pressing question is whether the high rate of psychosis in VCFS provides a shortcut to a gene within the deleted region that is involved in susceptibility to schizophrenia in cases without a deletion. Support for this hypothesis is provided by the fact that several linkage studies have reported evidence for a schizophrenia locus on 22q (see above), and the bin spanning 22q11 is one of the most significant regions to emerge from the meta-analysis by Lewis et al. 60 Finally, mice that are heterozygously deleted for orthologues of a subset of the genes that are deleted in VCFS have cardiovascular abnormalities similar to those observed in VCFS. 78 They also show sensorimotor gating and memory impairments, both of which have been implicated as endophenotypes in schizophrenia. 79 Further studies of models of this sort may well allow the genetic basis for the behavioural and psychiatric phenotypes in VCFS to be determined, which in turn might point to genes and pathways relevant to schizophrenia.
Association studies
Functional candidate genes Screening the whole genome by association presents difficulties because of the large, and as yet unknown, number of markers required to achieve comprehensive coverage. To date, therefore, most researchers have chosen to undertake positional and functional candidate gene studies. Owing to doubts concerning the robustness of linkage findings in schizophrenia, most studies to date have focused upon functional candidate genes even in the absence of a consensus as to what constitutes such genes.
The most obvious candidate genes derive from the neuropharmacological literature. Thus, genes involved in dopaminergic and serotonergic neurotransmission have received a great deal of attention. With recent developments in genome analysis and the recent publication of a working draft of the human genome sequence, 80 these data are being rapidly extended to other systems including the glutamatergic, GABAergic, and genes involved in neuromodula-tion and neurodevelopment. 81 It is impossible for us to present the results of the many candidate gene studies that have been published or reported at meetings. However, for the reasons outlined, the overwhelming number of negative reports cannot be considered as definitive exclusions of small genetic effects. Moreover, with perhaps the two exceptions we discuss below, no positive finding has received sufficient support from more than one group to suggest a true association with even a modest degree of probability.
5HT2a
The serotonergic system is a therapeutic target for several antipsychotic drugs. The first genetic evidence for its involvement in schizophrenia came from reports of association with the T102C polymorphism in the HTR2A gene that encodes the 5HT2a receptor. 82, 83 Conflicting data were subsequently reported, but the presence of an association with an odds ratio (OR) for the C allele of approximately 1.2 was supported (P¼0.0009) by our meta-analysis of all the data available in 1997 based upon more than 3000 subjects. 84 We have also recently typed a further sample of 681 cases and 690 controls, and failed to find association (in preparation). In contrast, Lohmueller et al 85 have recently published a metaanalysis of 28 studies, excluding the initial report and obtained significant support for an association with the C allele. However, the relative risk was only 1.07 and would require a study of 6900 case-control pairs to achieve 80% power at Po0.05. These findings suggest that variation in HTR2A confers at most a very small effect on disease susceptibility. Another possibility is that variation at this locus modifies the disease phenotype rather than conferring disease susceptibility per se.
Another reason to be skeptical about the putative association is that there are no variants yet detected in the gene that clearly alter receptor function or expression. Bray et al 86 have also obtained data that strongly suggest an absence of even moderately common cis-acting factors, including the 102T/C and À1438G/A variants that cause variability in 5HT2A mRNA expression in adult brain. These data therefore suggest that observations of differential expression of 5HT2A mRNA in schizophrenic brain are most likely a consequence of the illness or its treatment. Moreover, they also reject the hypothesis that genetic associations at the 102T/C locus can be attributable to direct effects on mRNA expression, or are the result of linkage disequilibrium (LD) with another variant with this effect. One caveat to this assertion is that since Bray et al tested mRNA from only adult brain, the findings may not be relevant to 5HT2A expression in the developing nervous system. This might be relevant, because neurodevelopmental influences are likely in schizophrenia. It also remains possible that the 102T/C variant has an intrinsic effect on post-transcriptional events, for example translation. 87 
Dopamine receptor genes
The dominant neurochemical hypothesis of schizophrenia involves dysregulation of the dopaminergic system, with disordered transmission at the dopamine D2 receptor widely favoured. However, association analyses of DRD2 to date have essentially been negative, although recently, three groups, two Japanese 88,89 and one Swedish, 90 have implicated a polymorphism in the promoter, which alters DRD2 expression in vitro. Unfortunately, the largest single study to date found no evidence for association. 91 Furthermore, when the UK data from this study were combined with a large dataset from Scotland, the allele that was associated with schizophrenia in the other three studies was actually significantly less common in the patient group. 92 This finding has been interpreted as suggestive that the polymorphism tested in these studies is simply a marker for the true susceptibility variant and that the association is due to LD. While it is reasonable to attribute the reversal of allelic association to LD differences between samples of different ethnic origins, the explanation would be more convincing if the same allele was associated in both UK and Swedish samples.
The dopamine hypothesis has received support from studies of DRD3, which encodes the dopamine D3 receptor. Association has been reported between schizophrenia and homozygosity for a Ser9Gly polymorphism in exon 1 of this gene. 93 As expected, positive and negative reports followed, but our metaanalysis of data from over 5000 individuals 94 concluded in favour of association although the effect size was small (OR¼1.23) but nominally significant (P¼0.0002). Recent meta-analysis of 48 studies excluding the original report has also supported the presence of association, though once again the relative risk (1.13) was small. 85 Given the paucity of convincing data that the Ser9Gly polymorphism has functional consequences and its location outside the ligand-binding and signaltransduction domains, Anney et al 95 set out to determine whether the association with schizophrenia reflects LD with pathogenic variants that are further upstream. They identified three additional upstream exons, two putative promoter regions and a number of novel SNPs. However, none of the latter was associated with schizophrenia, implying that the regulatory region of DRD3 does not play a major role in predisposition to schizophrenia.
In summary, if DRD3 and 5HT2A play a role in genetic susceptibility to schizophrenia, it seems likely that they do so as a part of the polygenic chorus rather than as one of the principal oligogenic players.
Positional candidate genes recently implicated in schizophrenia
The convergence of several suggestive linkages for schizophrenia across a number of studies has rekindled enthusiasm for the linkage/positional ge-netics paradigm, particularly since successes in other complex diseases, including diabetes, 96 Crohn's disease, 97, 98 asthma, 99 and general autoimmunity 100 have shown that some rather influential voices may have been too pessimistic (eg Weiss and Terwilliger 101 ). This enthusiasm now appears to be well placed, as in 2002, several putative susceptibility genes for schizophrenia were also identified by positional genetics. Although caution is still required, two of these, dysbindin (DTNBP1) 102 and neuregulin (NRG1), 35 have been replicated in at least two independent samples (see below), making schizophrenia one of the greatest successes in pure positional genetic approaches to complex diseases.
Dysbindin (DTNBP1)
In an attempt to identify the specific gene(s) responsible for their earlier linkage to 6p, 25 Straub et al 102 undertook systematic LD mapping using the same 270 Irish multiply affected families in which the linkage had been found. Significant evidence for association was found with several SNPs and haplotypes, a finding that remained under a conservative analysis which included only a single affected from each nuclear family (P¼0.008-0.0001 for three-marker haplotypes). Although the findings suggested DTNBP1 as a susceptibility gene for schizophrenia, Straub et al were unable to identify the specific susceptibility variants.
At the time of writing, we are aware of follow-up studies by only three other groups (including ourselves) based upon five samples. Despite this modest number of studies, the evidence for DTNBP1 as a susceptibility gene for schizophrenia is now strong. The first study was based upon 78 German and Israeli families showing evidence for linkage to 6p, and 127 proband-parent trios, mainly from Germany but including a small number of subjects from Hungary. 103 Both samples (linkage families and trios) independently gave evidence in favour of association, and when they were combined, the evidence in favour of association was strong (combined P¼0.00001 for a three-marker haplotype).
Disappointingly, a second study based upon 219 Irish cases and 231 controls initially failed to find evidence for association, 104 as did our own large casecontrol study of 708 cases and 711 controls. 105 However, we went on to screen all the known and predicted exons as well as four putative alternative DTNBP1 promoters for sequence variation. When novel SNPs, particularly one from the most 5 0 promoter, were included with markers from the original study, highly significant evidence for association was obtained (minimum global P¼0.00005 105 ). When the same markers were examined in the Dublin sample that was previously negative, 104 the specific risk haplotype we observed was significantly more common in the patient sample (P¼0.017, two-tailed, 1 df 105 ). Taken together, the data from five samples studied by four independent groups provide compelling evidence that variation in DTNBP1, or a neighbouring gene, confers susceptibility for schizophrenia. However, individual SNPs or haplotypes that directly increase disease susceptibility have not yet been found. The Cardiff and Dublin samples have identical risk haplotypes, but these differ from those in the other studies. It seems likely that the differences reflect allelic heterogeneity at the DTNBP1 locus. 103 Our direct gene analysis suggests it is unlikely that susceptibility is conferred by nonsynonymous variation, but there is evidence in the general population for cis-acting variants that alter DTNBP1 expression in the human brain. 106 These are clearly prime candidates for being the true susceptibility variants, but so far they remain unidentified.
Neuregulin 1 (NRG1)
The deCODE Genetics group identified several risk haplotypes for schizophrenia around NRG1 after performing systematic LD analysis across a linkage region they, and others (Figure 1 ), had identified on 8p. 35 Each shared a core haplotype (P¼0.000087-0.0000067, 1 df, OR¼2.1). 35 deCODE subsequently replicated the specific risk haplotype in a large Scottish sample (P¼0.00031, 1 df, OR¼1.8), 107 as have we in a somewhat larger sample (P¼0.04, 1 df, OR¼1.25). 108 In our sample, the OR was somewhat greater in cases with an affected first-degree relative (OR¼1.65, P¼0.019, 1 df).
These studies strongly suggest that variation in NRG1 or a closely linked gene confers susceptibility to schizophrenia, though, as for DTNBP1, the specific risk alelles and pathogeneic mechanisms are unknown. Unlike the findings with DTNBP1, there is a striking degree of homogeneity, at least at the level of the associated haplotype, although whether this will apply to populations of non-Northern European ancestry remains to be seen. As is generally the case with follow-up studies, 109 the estimated effect size is tending to drift downwards, and this may have major implications for the numerous replication attempts that can be expected based upon relatively small samples.
It has been proposed that NRG1 might influence disease susceptibility by altering the expression and activities of a broad range of neuroreceptors, particular NMDA glutamatergic receptors.
107 NRG1 is also an important regulator of glial cells and myelination. [110] [111] [112] Given the considerable body of evidence implicating white matter abnormalities in schizophrenia, 113 an alternative hypothesis is that altered NRG1 function results in abnormal myelination. Yet another hypothesis, extensively outlined elsewhere, is that altered NRG1 leads to a functional deficiency of glia, and that this results in synaptic destabilisation. 114 Interestingly, the most striking finding from one of the few published global expression profiling studies of schizophrenia was that six genes, all strongly expressed in oligodendrocytes and implicated in the formation of myelin sheaths, were downregulated in the postmortem brains of schizophrenics. 115 Surpris-ingly, given the obvious challenges and artefacts involved in studies of postmortem brain, many of these changes have been independently replicated (cited in Davis et al
113
) and one of these, ERBB3, belongs to a family of neuregulin receptors. The subsequent implication of NRG1 in schizophrenia provides striking evidence that even in the most difficult tissue of all (human brain) and in one of the most difficult phenotypes (schizophrenia), global expression studies can identify aetiologically relevant pathways (and see also RGS4 below).
G30, G72 and D-amino-acid oxidase The third gene to be reported based upon a pure positional genetics approach was identified within the 13q22-34 linkage region. The Genset group in France obtained single point association evidence after examining a 5 Mb region using 191 SNP markers in just over 200 French-Canadian schizophrenic cases and controls. Examination of haplotypes revealed much stronger evidence for association, with P¼3 Â 10 À6 even after correcting for multiple testing of haplotypes. The authors identified two possible genes, which were overlapping but located on opposite DNA strands, in the associated region that might account for the finding, and designated them G72 and G30. There were no homologues for either of the genes in databases, nor did sequence analysis of the putative ORFs reveal any likely function. Both were expressed in the brain (and other tissues), but only G72 gave a product after in vitro translation, designated PLG72. On this basis, G72 was selected for further functional analysis, revealing a possible interaction between its product PLG72 and D-amino-acid oxidase (DAO or DAAO). By genotyping eight SNPs across the DAO gene, Chumakov et al were then able to demonstrate that four intronic SNPs in partial LD were also associated with schizophrenia (P¼0.001) in the French-Canadians. Although the function of DAO is largely unknown, it has been proposed that it may act as a detoxifying enzyme against exogenous D-amino acids. However, it also appears to modulate the level of D-serine in brain, which in turn appears to be an endogenous modulator of NMDA glutamatergic receptors. 116 Moreover, there is evidence that Dserine levels are reduced in the brain and blood of patients with schizophrenia. 117, 118 Chumakov et al therefore speculated that the G72/DAO associations support the long-standing hypothesis of abnormal glutamatergic transmission in schizophrenia.
The statistical evidence for association between G72/G30 and schizophrenia is impressive, as is the additional finding of association with the interacting gene DAO. Unfortunately, at the time of writing, there are no published independent replications for either finding. Chumakov et al 119 report some evidence for single-marker association in the region of G72/G30 in an additional Russian sample of just less than 200 cases and controls, but surprisingly did not report the results of haplotype analysis or the results of analysis of DAO in that sample. These and other analyses by completely independent groups are keenly awaited. However, encouraging data have recently been reported regarding the G72/G30 complex in bipolar disorder (BPD). Many have viewed BPD and schizophrenia as imperfectly separated disorders sharing at least some aetiological factors in common. Recently, evidence for association between markers in the G72/ G30 complex and BPD (Hattori et al 120 ) has been reported in two samples. These findings cannot be considered as replicating those in schizophrenia, but if the findings in both BPD and schizophrenia are replicated, it will have important ramifications for the classification of major psychiatric disorders.
RGS4 Unlike NRG1, DTNBP1 and G30/72, which were identified by pure positional genetics, molecular genetic analyses of RGS4 (regulator of G protein signalling-4) 121 were initiated because it is a differentially expressed functional and a positional candidate gene for schizophrenia. Microarray studies of global gene expression, subsequently confirmed by single-gene expression analysis, revealed that RGS4 expression was downregulated in the brains of patients with schizophrenia. 122, 123 RGS proteins act to dampen the effects of agonists at G-protein-coupled receptors (GPCRs). Since the overactivity at several such GPCRs, particularly dopamine, has been implicated in schizophrenia, this observation appeared to be plausibly related to pathogenesis. 121 Moreover, RGS4 maps to 1q21-q22, a region of the genome that has previously been implicated by linkage in schizophrenia (see above).
Chowdari et al 121 investigated two proband-parent trio samples from the US and from India, as well as a third small sample recruited by the NIMH Collaborative Genetics Initiative. Significant associations were independently obtained in each of the US samples for haplotypes encompassing four SNPs in the 5 0 flanking sequence and first intron of RGS4. As for DTNBP1, different alleles in different samples defined the risk haplotype. Significant association was not obtained for the larger Indian sample, but the overall evidence for association was significant across all the three samples (P¼0.0027). We (unpublished) have been able to replicate the evidence for two of the four SNPs that had previously been individually associated. Moreover, in subjects with familial schizophrenia, we were able to replicate association with the original three-and four-marker haplotypes, and obtained somewhat stronger evidence for a haplotype constructed from two of the four markers. Although three samples have shown independently significant evidence in favour of association, the cumulative evidence for RGS4 as a susceptibility gene for schizophrenia is still modest, and further replication studies are urgently required.
Catechol-O-methyl transferase (COMT) COMT is a candidate gene for schizophrenia not only because it encodes a key dopamine catabolic enzyme, but also because it is one of the genes deleted in VCFS. The COMT protein occurs in two distinct forms: a soluble form found in the cell cytoplasm (S-COMT) and a longer, membrane-bound form (MB-COMT). In most assayed tissues, the S-COMT form predominates, accounting for around 95% of total COMT activity. 124, 125 However, the MB-COMT form is the more prevalent species in brain. 126 The COMT gene contains a valine-to-methionine (Val/Met) substitution at codon 108 and 158 in the S-COMT and MB-COMT transcripts, respectively. 127 The Val variant of S-COMT is reported to have greater activity and thermostability than the Met variant, 127, 128 134, 135 providing a possible mechanism by which COMT might act as a susceptibility or modifying locus for schizophrenia.
Recently, Shifman et al 136 reported a large study of COMT in schizophrenia, including over 700 patients and 4000 controls. Despite the very large sample, the evidence for association with the Val/Met polymorphism was modest (by allele, P¼0.024), whereas two other polymorphisms (intron 1 and 3 0 flanking region) were highly significantly associated, as was the haplotype of all the three markers (P¼9.6 Â 10 À8 , 1 df, OR 1.46). This finding, though statistically impressive, is so far unreplicated. Our own sample, which has a power greater than 0.95 to replicate, shows no evidence for association with any of the three SNPs or the haplotype (in preparation). The study of Shifman et al was performed upon a sample of Ashkenazi Jews, on the premise that they are relatively homogeneous for genetic (and environmental) risk factors. If this is correct, then differences in the genetic architecture of other samples will make interpretation of negative data like our own difficult.
The findings of Shifman suggest that, if variation in COMT is associated with increased risk of schizophrenia, then this is not attributable to the Val/Met polymorphism. Given that COMT degrades dopamine, that most treatments for schizophrenia block dopaminergic transmission while drugs that enhance it are psychotomimetic, and that deletion of 22q11, including COMT, is associated with schizophrenia, Bray et al 137 postulated that it is more plausible that the haplotype associated with schizophrenia is associated with low COMT expression rather than with high activity. They were able to show that the COMT haplotype implicated in schizophrenia 136 is indeed associated with lower expression of COMT mRNA, and that the SNP in the 3 0 flanking region that was most strongly associated with schizophrenia is actually transcribed in human brain and exhibits significant differences in allelic expression, with a lower relative expression of the associated allele. Their results support the hypothesis that the haplotype implicated in schizophrenia susceptibility may exert its effect, directly or indirectly, by downregulating COMT expression. The importance of this for schizophrenia biology is that the findings are compatible with the classic hyperdopaminergic theory of schizophrenia. They also suggest that reduced expression of COMT by virtue of its deletion might underlie the increased risk of schizophrenia seen in VCFS.
Proline dehydrogenase (PRODH) Liu et al 138 reported a complex pattern of associations between SNPs in the PRODH gene and schizophrenia. The PRODH gene was studied for two reasons. First, it is located in the VCFS deleted region. Second, mice with an inactivated PRODH gene have abnormalities of sensorimotor gating similar to those that some consider a trait marker for schizophrenia. 139 The authors also found that mis-sense substitutions in exon 12 of PRODH, which appeared to arise by virtue of gene conversion from a sequence they designate as PRODH2-P (AC007663.29), were also more common in schizophrenics. The associated haplotype and the mis-sense substitutions in exon 12 appeared to act independently as risk factors for schizophrenia, and this was more pronounced in juvenile onset schizophrenia or when the onset was in childhood.
The first replication attempt examined only the most significant SNP in a small sample of Chinese parent-proband trios, but failed to find any evidence for preferential transmission. 140 We examined PRODH in more detail using our large case-control sample, a sample of VCFS probands with and without schizophrenia, and a sample of 55 proband-parent trios with juvenile onset schizophrenia. Despite the fact that each sample had 495% power to replicate the findings, in none did we find evidence for association between either the putative PRODH risk haplotype or the mis-sense substitutions. 140, 141 We also screened the complete cDNA sequence of PRODH and its pseudogene for novel sequence variants. Again, none were associated with schizophrenia. 141, 142 Given the high power to replicate the previous findings, our data suggest that genetic variation in PRODH is unlikely to be associated with increased risk of schizophrenia, and that the first positive findings are most likely due to chance.
Conclusions
After false starts and a more than a decade of hard work, schizophrenia is at last yielding its secrets to molecular genetics. The weight of evidence now strongly favours NRG1 and DTNBP1 as susceptibility loci, though work remains before we understand precisely how genetic variation at each locus confers susceptibility and protection. Both associations are with inferred haplotypes rather than variants with manifest functional consequences, although, in the case of DTNBP1, we know that variation within this gene does alter gene expression. 106 In both cases, the relative risk is small (o2.5) and cannot fully explain the linkage finding in the relevant region. These observations could suggest that the associated polymorphisms/haplotypes are in LD with pathogenic variants elsewhere in the associated gene or in a neighbouring gene. Alternatively, association may arise not from a single variation in the relevant gene but from the combined effect of several different variants. Both of these situations apply to complex traits in Drosophila, 143 and have been found in human diseases. [144] [145] [146] It is also possible that the respective linkages reflect variation at two or more linked loci.
The evidence for COMT, RGS4 and G72 is promising but not yet persuasive, but more studies in appropriately large samples should resolve the issue in the coming months. While further replications remain the top priority, the respective contributions of each gene, relationships with aspects of the phenotype, the possibility of epistatic interactions between genes and functional interactions between the gene products will all need investigation. The latter will help identify the molecular processes involved, and whether the genes act via a common pathway.
These successes of positional genetics are immensely encouraging for psychiatry. First, the existence of several promising linked regions suggests that other susceptibility genes for schizophrenia are likely to be found in the coming years. The loci identified so far only explain a small proportion of the genetic risk for schizophrenia. The imperative now must be to follow up other regions of schizophrenia linkage. Second, these findings suggest that similar approaches should be successful in identifying genes for other psychiatric disorders where replicated linkages have been found, such as late-onset Alzheimer's disease, BPD, autism and dyslexia. 147 Advances in genotyping technology and the establishment of several consortia collecting large samples of families and unrelated cases are further grounds for optimism. The ability of positional genetics to implicate novel genes and pathways in the pathogenesis of schizophrenia has already opened up new vistas for neurobiological research, 148 and we can expect more in the coming years. Genetic studies of schizophrenia have travelled a long and sometime rocky road, but all the signs are that now they are poised to deliver crucial insights into the nature of one of the most severe and debilitating mental illnesses.
